4/10/2026 7:54:08 PM What Happens in Delaware When a Structure Collapses? By Matthew R. Fogg Keith E. Donovan A parking garage collapse in South Philadelphia this week is a stark example of how quickly a structural failure can escalate, from a...
4/10/2026 5:12:38 PM Morris James Files Nearly 30 Cases in the Depo-Provera Multidistrict Litigation By Keith E. Donovan Matthew R. Fogg Morris James has filed 29 cases in the Depo-Provera multidistrict litigation, adding to the growing body of claims alleging that women...
4/3/2026 6:25:08 PM Morris James Investigating Olympus Scope Infection Claims By Keith E. Donovan Matthew R. Fogg Morris James LLP is now accepting cases on behalf of patients who developed serious infections after an endoscopy, gastroscopy,...
4/1/2026 2:27:37 PM Dupixent for Children: What Parents Should Ask Their Doctor About Cancer Risk By Keith E. Donovan Matthew R. Fogg Dupixent (dupilumab) has been a genuine breakthrough for many families. For children with moderate-to-severe eczema, asthma, and other...
3/24/2026 8:08:38 PM Who Is Eligible to File a GLP-1 Vision Loss Lawsuit? Understanding Criteria, Timing, and Next Steps By Keith E. Donovan Matthew R. Fogg Ashley C. Curran Morris James is investigating claims that Ozempic, Wegovy, and other GLP-1 medications have been linked to serious, permanent vision...
3/20/2026 8:33:37 PM Morris James Investigating GLP-1 Drug-Related Vision Loss Claims By Keith E. Donovan Matthew R. Fogg Morris James LLP is now accepting cases on behalf of patients who suffered serious vision loss after taking GLP-1 medications such as...
3/20/2026 6:43:07 PM FDA Class I Recall of FreeStyle Libre 3 Sensors: Practical Steps and Legal Considerations By Matthew R. Fogg Keith E. Donovan By: Keith Donovan and Matthew Fogg Key Takeaways The FDA has identified a Class I recall (its most serious type) involving certain...
3/19/2026 5:06:37 PM FDA Expands Dupixent for Children Amid Growing CTCL Concerns By Keith E. Donovan Matthew R. Fogg By: Keith Donovan and Matthew Fogg The FDA has expanded approval of Dupixent® (dupilumab) for children aged six and older with allergic...